Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Mar;30(2):301-7.
doi: 10.1007/s10875-009-9352-2. Epub 2010 Jan 15.

Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis

Affiliations
Comparative Study

Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis

Ralph Shapiro. J Clin Immunol. 2010 Mar.

Abstract

Background: Subcutaneous immunoglobulin (SCIg) replacement therapy for primary immune deficiency disease (PIDD) is a safe, effective, and convenient alternative to intravenous Ig (IVIg) therapy. Although SCIg is typically administered weekly by infusion pump, administration by a rapid push technique may provide a greater degree of convenience. Rapid push administration has been an option at the author's clinic for several years. We report experience with a cohort of patients given a choice between rapid push and standard pump administration.

Methods: This was a retrospective chart review of PIDD patients at a single site who initiated treatment with SCIg (16% solution) therapy between January 1, 2006 and April 1, 2008. Patients selected either infusion pump or rapid push administration after receiving a description and demonstration of each method and training for home self-administration. Demographics, dose, adverse events (AEs), serum immunoglobulin G (IgG) levels, and therapy disposition (discontinued, switched technique) were recorded on a standardized data collection form.

Results: Charts for 104 patients (45 male, 59 female; mean age, 21.1 years; range, 0.5-67.6 years; SD = 17.9 years) were reviewed. Seventy-four patients (71%) chose rapid push. Mean SCIg dose was 32.11 g/month (range, 1.92-89.6 g/month; SD = 8.3 g/month) split into an average of 3.11 times per week. Volume per site ranged from 3 to 20 mL, typically administered over 5-20 min and at one site. Mean serum IgG levels did not differ significantly by administration method: pump, 1,153.06 mg/dL (SD = 240.8); rapid push, 1,225.8 mg/dL (SD = 299.8). Local infusion-site reactions were the most common AEs and were experienced by one third of patients in each group. Only two patients discontinued therapy because of an AE.

Conclusion: The results suggest that PIDD patients prefer SCIg administered as a rapid push rather than as conventional pump infusion. Serum IgG levels were comparable between methods, and safety was similar, if not slightly better, with rapid push. Rapid push offers the potential for even greater convenience than the pump infusion technique, although these results should be confirmed in prospective studies.

PubMed Disclaimer

References

    1. J Clin Immunol. 2006 Jul;26(4):400-5 - PubMed
    1. J Allergy Clin Immunol. 2004 Oct;114(4):936-42 - PubMed
    1. BioDrugs. 2007;21(2):105-16 - PubMed
    1. J Clin Immunol. 2006 May;26(3):265-73 - PubMed
    1. J Clin Immunol. 1994 Mar;14(2):90-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources